Business
While Baseline Therapeutics declined to disclose its starting capital, the startup said it will use the funds to push its GLP-1 asset BT-001 into late-stage development, with two trials planned this year.
FEATURED STORIES
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The new company, FS Development II, announced this week it raised $175 million in an upsized offering at $10 per share. The shares will be listed on the Nasdaq under the ticker symbol FSII.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Eli Lilly is jumping into the RIPK1 chase, paying $125 million up front to partner with Rigel Pharmaceuticals to co-develop its lead RIPK1 inhibitor program across all indications.
BeiGene’s Bruton’s kinase inhibitor Brukinsa (zanabrutinib) could be on its way for regulatory approval as a potential treatment for Waldenström’s macroglobulinemia (WM), a type of non-Hodgkin lymphoma.
Nektar Therapeutics has entered into a financing and co-development collaboration with SFJ Pharmaceuticals which will advance the development of investigational CD122-preferential IL-2–pathway agonist bempegaldesleukin for head and neck cancer.
The company announced this morning it is merging with special purpose acquisition company Alpha Healthcare Acquisition Corp. and will begin trading on the Nasdaq exchange under the ticker symbol “HUMA” in the second quarter of 2021.
The Foundation will offer funding for development of the therapy.
In 2020, Vir and GlaxoSmithKline partnered to develop strategies against COVID-19. The two companies have expanded that collaboration to include work into new treatments for influenza and other respiratory viruses.
The company’s lead drug candidate, Repotrectinib, is currently in Phase I/II clinical studies to target non-small cell lung cancer (NSCLC) in patients with a ROS1 or NTRK metastatic mutation.
AstraZeneca Chief Executive Officer Pascal Soriot is seeing a significant return on the fruits of his company’s labor in 2020. Soriot’s annual compensation jumped a bit from the previous year to $21.4 million.